Cargando…
Developing oncolytic Herpes simplex virus type 1 through UL39 knockout by CRISPR-Cas9
OBJECTIVE(S): Oncolytic Herpes simplex virus type 1 (HSV-1) has emerged as a promising strategy for cancer therapy. However, development of novel oncolytic mutants has remained a major challenge owing to low efficiency of conventional genome editing methods. Recently, CRISPR-Cas9 has revolutionized...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mashhad University of Medical Sciences
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395182/ https://www.ncbi.nlm.nih.gov/pubmed/32774817 http://dx.doi.org/10.22038/ijbms.2020.43864.10286 |